Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Boehringer Ingelheim
AstraZeneca
McKinsey
Dow

Last Updated: January 28, 2020

DrugPatentWatch Database Preview

COMETRIQ Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Cometriq, and when can generic versions of Cometriq launch?

Cometriq is a drug marketed by Exelixis and is included in one NDA. There are three patents protecting this drug.

This drug has one hundred and forty-nine patent family members in twenty-nine countries.

The generic ingredient in COMETRIQ is cabozantinib s-malate. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cabozantinib s-malate profile page.

US ANDA Litigation and Generic Entry Outlook for Cometriq

Cometriq was eligible for patent challenges on November 29, 2016.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Drug patent expirations by year for COMETRIQ
Drug Prices for COMETRIQ

See drug prices for COMETRIQ

Recent Clinical Trials for COMETRIQ

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of California, IrvinePhase 2
Emory UniversityPhase 2
Liza Villaruz, MDPhase 2

See all COMETRIQ clinical trials

Recent Litigation for COMETRIQ

Identify potential future generic entrants

District Court Litigation
Case NameDate
Exelixis, Inc. v. MSN Laboratories Private Limited2019-10-29

See all COMETRIQ litigation

Pharmacology for COMETRIQ
Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors
Synonyms for COMETRIQ
1,1-Cyclopropanedicarboxamide, N'-(4-((6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- fluorophenyl)-
1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-
1,1-Cyclopropanedicarboxamide,N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-
1C39JW444G
849217-68-1
AB0033751
AB01565831_02
ABP000796
AC-25082
AKOS025142112
AOB87755
AS-16277
BC267213
BCP02591
BCP9000470
BCPP000308
BDBM50021574
BMS 907351
BMS-907351
BMS907351
BRD-K51544265-001-01-8
C28H24FN3O5
Cabometyx (TN)
Cabozantinib
Cabozantinib (USAN)
Cabozantinib (XL-184)
Cabozantinib (XL184, BMS-907351)
Cabozantinib [USAN:INN]
Cabozantinib XL-184
Cabozantinib/XL184
cc-10
CHEBI:72317
CHEMBL2105717
Cometriq (TN)
CS-0278
cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide(4-fluoro-phenyl)-amide
cyclopropane-1,1-dicarboxylic acid[4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide
D10062
DB-023624
DB08875
DTXSID10233968
EX-A075
FT-0664184
GTPL5887
HMS3654G06
HY-13016
J-523016
KB-62285
MolPort-021-804-939
n-(4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N-(4-f
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4 fluorophenyl)cyclopropane-1,1-dicarboxamide
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide
N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
N'-[4-[(6,7-DIMETHOXY-4-QUINOLINYL)OXY]PHENYL]-N-(4-FLUOROPHENYL)-1,1-CYCLOPROPANEDICARBOXAMIDE
NCGC00263164-01
NCGC00263164-14
ONIQOQHATWINJY-UHFFFAOYSA-N
PubChem22994
Q-3907
QCR-122
RL05229
s1119
SB20062
SC-85393
SCHEMBL360795
SR-01000941569
SR-01000941569-1
SW218093-3
SYN1138
UNII-1C39JW444G
X7477
XL 184
XL 184, XL-184, 1021950-26-4
XL-184
XL-184 (Cabozantinib BMS907351)
XL-184 free base (Cabozantinib)
XL-184,Cabozantinib, BMS-907351
XL184
XL184 free base
XL184 free base - Cabozantinib
ZINC70466416

US Patents and Regulatory Information for COMETRIQ

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Exelixis COMETRIQ cabozantinib s-malate CAPSULE;ORAL 203756-001 Nov 29, 2012 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Exelixis COMETRIQ cabozantinib s-malate CAPSULE;ORAL 203756-002 Nov 29, 2012 RX Yes No   Start Trial   Start Trial Y   Start Trial
Exelixis COMETRIQ cabozantinib s-malate CAPSULE;ORAL 203756-001 Nov 29, 2012 RX Yes Yes   Start Trial   Start Trial   Start Trial
Exelixis COMETRIQ cabozantinib s-malate CAPSULE;ORAL 203756-002 Nov 29, 2012 RX Yes No   Start Trial   Start Trial   Start Trial
Exelixis COMETRIQ cabozantinib s-malate CAPSULE;ORAL 203756-001 Nov 29, 2012 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Exelixis COMETRIQ cabozantinib s-malate CAPSULE;ORAL 203756-001 Nov 29, 2012 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Exelixis COMETRIQ cabozantinib s-malate CAPSULE;ORAL 203756-002 Nov 29, 2012 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for COMETRIQ

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2213661 1490053-4 Sweden   Start Trial PRODUCT NAME: CABOZANTINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/13/890 20140326
2213661 PA2014033 Lithuania   Start Trial PRODUCT NAME: CABOZANTINIBUM; REGISTRATION NO/DATE: EU/1/13/890/001 - EU/1/13/890/003 20140321
2213661 43/2014 Austria   Start Trial PRODUCT NAME: CABOZANTINIB ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/13/890/001-003 (MITTEILUNG) 20140326
2213661 14C0067 France   Start Trial PRODUCT NAME: CABOZANTINIB ET TOUTE FORME THERAPEUTIQUEMENT EQUIVALENTE COUVERTE PAR LE BREVET DE BASE,INCLUANT SES SELS PHARMACEUTIQUEMENT EQUIVALENTS.; REGISTRATION NO/DATE: EU/1/13/890 20140326
2213661 CA 2014 00039 Denmark   Start Trial PRODUCT NAME: CABOZANTINIB, INKLUSIVE FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER CABOZANTINIB (S)-MALAT; REG. NO/DATE: EU/1/13/890/001-003 20140321
2213661 PA2014033,C2213661 Lithuania   Start Trial PRODUCT NAME: KABOZANTINIBAS IR JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS; REGISTRATION NO/DATE: EU/1/13/890/001 - EU/1/13/890/003 20140321
2213661 300678 Netherlands   Start Trial PRODUCT NAME: CABOZANTINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140326
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Merck
McKinsey
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.